What top creators are saying about UnitedHealth Group Incorporated(UNH)— Page 3

After being 'obliterated', the stock is viewed as a 'potential deep value opportunity' and 'really freaking interesting' at its current levels around $282, now yielding over 3%.

Viewed as a fundamentally strong, undervalued 'buy and hold' candidate for patient investors after being beaten down, but a quick recovery is not expected.

Viewed as an industry leader and a safer investment in the sector. A guest is adding to their position below $300, seeing weakness as a buying opportunity.

The recent dip is framed as a clear buying opportunity for a 'ridiculously undervalued' company. A conservative valuation model suggests a stock price of $450 by 2030. The primary risk is a DOJ investigation.

Called 'objectively undervalued'. A conservative analysis yields a $450 price target. Broke out of a consolidation box, but needs to hold above $324.64 to continue. Faces headline risk from a DOJ investigation.

Highlighted as an undervalued value stock that performed well during a market rotation. It was specifically mentioned as a 'safety play' in case of a recession or growth scare.

Viewed as a deep value play, down 40% YTD, with a cheap valuation (11x forward earnings) and significant insider buying. An options trade was placed betting the stock will be above $460 in 2.5 years.

Viewed as a 'deep value play' trading at a low valuation with 50% upside potential. The speaker initiated a long-term bullish call debit spread trade based on insider buying and its defensive nature.

Viewed as significantly undervalued, trading at just 11 times free cash flow. A long-term options strategy was initiated, targeting a price of $460 by December 2027. The company is described as a 'blue chip business' with a durable moat and has seen recent insider buying.